The interactions between pathogenic bacteria and the host need to be resolved at the molecular level in order to develop novel antiadhesive drugs and vaccines. We have previously identified strepadhesin, a novel glycoprotein-binding activity in Streptococcus pyogenes binding to thyroglobulin, submaxillar mucin, fetuin, and asialofetuin. The activity is known to be regulated by Mga, a regulator of streptococcal virulence factors, and is carried by the surface-associated streptococcal cysteine protease, SpeB. In the present study, we focused on the high strepadhesin activity in an S. pyogenes strain (NZ131rgg) lacking SpeB expression. By extracting surface proteins from the bacteria, a new strepadhesin protein was identified, and mass spectrometric analysis and database search identified it as a putative pullulanase. The gene was cloned, and the recombinant pullulanase (PulA) exhibited pullulanase and starch hydrolyzing activity, as well as strepadhesin activity. Sequencing of the pulA gene revealed an open reading frame with 3,498 bp encoding a protein of 1,165 amino acids with a predicted molecular mass of 129 kDa. PulA exhibited properties typical for a gram-positive surface protein with a putative signal sequence and LPKTGE cell wall anchoring motif and contained the four highly conserved regions common to pullulanases. Mutant bacteria deficient in PulA expression showed diminished strepadhesin activity on bacterial dot blot assay and reduced adherence to thyroglobulin immobilized on microtiter plates. Thus, S. pyogenes strepadhesin activity is carried by a surface-bound pullulanase, which combines glycoprotein-binding and carbohydrate-degrading activities in the same molecule.In most infectious diseases, the initial event is the adherence of pathogenic organisms to the host. The process is in many cases mediated by the interaction between lectins on the surface of the infectious organism and carbohydrates on the host tissues. The interaction can be blocked by soluble carbohydrates, or analogous structures, recognized by the bacterial lectins or by antibodies binding to the lectins. This approach to prevent and treat infectious diseases, called antiadhesion therapy (5,29,30,52,59,60), is a highly promising approach in the fight against pathogens in the era of increasing antibiotic resistance. In order to develop novel antiadhesion drugs, however, we need to first characterize the interactions between bacterial adhesins and host receptors in molecular detail.Streptococcus pyogenes is a human pathogen that causes a variety of diseases, such as pharyngitis, impetigo, and erysipelas, and also life-threatening infections, necrotizing fasciitis, and toxic shock-like syndrome. The number of S. pyogenes infections, especially the severe ones, has been increasing since the beginning of the last decade (6, 12), and there are several reports concerning the appearance of S. pyogenes strains resistant to antibiotics (37,51). This emphasizes the need for new preventive methods and therapies against S. pyogenes infections.Ca...